VeRI BEAM

All recent reports establishing a roadmap to tackle the global, worldwide antimicrobial resistance (AMR) problem highlight the need to enlarge the current armamentarium beyond the sole “full antibiotic” model. Many efforts are being devoted to fulfil these needs both by academia and industry, as exemplified by the BEAM Alliance member portfolio (https://beam-alliance.eu/ba_pipeline). These new options include improved time-to-cure, anti-virulence, involvement of immune system, impact on flora, infection prevention, etc. both for animal and human medicine.

Completed project

However, while there is a clear path to Health Technology Assessment on antibiotic candidates (thanks to the EUCAST clinical breakpoint guidelines) no such established methodology is available for alternative antimicrobial treatments. Thus, any new treatment option faces the problem of lacking differentiation criteria to allow assessments of their products that do not have the possibility to be assessed by the classical MIC – PK/PD method. The clear definition of such criteria could benefit to the whole AMR research community. This uncertainty turns any such drug development into an undefined and risky market access condition. Consequently, private investors are reluctant to engage and to play a supporting role to pull-out promising candidates and bring them to the market. Most of the time, private companies learn or even co-build these requirements with (inter)national stakeholders, but this knowledge is rarely shared with e.g. academic labs or funding agencies, although it is of tremendous importance to anticipate pitfalls and avoid misuse of public funding.

The purpose of the VeRI BEAM Network is to implement a pilot action aiming at defining i) the above mentioned differentiation criteria and ii) the proper way to share the gained knowledge among AMR community. The pilot action will be used to validate a more general and long-term communication flow within the future JPIAMR-VRI between academic labs, and industrial and institutional actors in a non-competitive manner with a focus on innovative product development. Such a workflow will be helpful in anticipating R&D pitfalls and avoiding misuse of public funding.

For that purpose, the Network aims at:

  • Mapping the information needs both in terms of content and format expressed by academic and institutional actors;
  • Proposing an information workflow model;
  • Developing the differentiation criteria use case to challenge the foreseen model.

The proposed communication workflow model will ensure building capacity and strengthening capability of JPIAMR-VRI members through knowledge exchange mainly on the non-scientific side, but including business skills such as regulatory frameworks, manufacturing policies, marketing, technology or policy development. This can be part of a more general Training Plan to be implemented at the whole JPIAMR-VRI level. Finally yet importantly, the work focusing on the definition of new differentiation criteria is fully aligned with the goal of producing scientific evidence for developing policy and guidelines.

Network partners

  • Florence Séjourné, BEAM Alliance, France (Coordinator)

This network includes 26 partners, please click on the following link to see complete network composition: Network composition VeRI BEAM

When you get an infection, your doctor may give you an antibiotic. But on which ground is that specific pill being chosen to address your specific condition? It is sometimes quite difficult to choose between the different available antimicrobial drugs because they are basically compared on the basis of a single criterion: the required dose to kill or inhibit the pathogen measured in a specific (and sometimes irrelevant) experimental laboratory assay while the drug is being developed. In order to curb the AMR threat, innovators are now looking at the problem differently and are designing new approaches. Besides just killing the pathogen, drugs can exert other features that might be equally important such as the speed at which it kills the pathogen, the ability to circumvent existing resistance mechanism or pathogen-derived injuries to your organism, etc. But none of these features are being rigorously evaluated during the drug development and approval processes, because the regulatory pathways intended to validate the performance of all these new approaches are not ready.

The goal of our network was to highlight the need to develop new criteria to evaluate more comprehensively the different features exerted by an antimicrobial drug to enable an informed prescription, with the drug that is the most suited for your particular condition. Improving the differentiation of the AMR products would increase both their clinical value (to match the patient’s needs with the drug actions) and their market value (more benefits for the patient and the health system deserve a better price).

As a first step we defined a categorization framework allowing the identification of one or multiple medicinal activity for each drug. Then, we started discussing with the regulatory agencies to agree on the way to establish new criteria. We then focus on a particular category, regrouping microbes able to modulate their metabolism to become tolerant to the antimicrobials. Finally, we identified relevant assays to support the definition of appropriate evaluation criteria and designed a decision tree to help clinicians handle such medical cases.

The regulatory path to get new criteria accepted is a long way to go; but the work has been initiated and must be pursued to improve the way drugs are being developed and the valuable antimicrobials are prescribed.

Project resources

Call

TRANSLOCATION-transfer (TT)

There is an urgent need for discovery and development of new drugs to combat multi-resistant organisms. The search for new drugs is cumbersome, particularly because the current business model for antibiotics in the pharmaceutical industry has been stalled because of the poor return on investment.

Ongoing project

In response to the pharmaceutical industry stepping back from antibiotic discovery, multiple public efforts, including the JPIAMR and IMI ND4BB, as well as the efforts of Biomedical Science (BMS) European Research Infrastructures community have stepped in to fill the gap. In this project, the TT network will set up a knowledge sharing network, Translocation-Transfer bringing together experts from with two major publically funded programs, with the goal to improve the process of academically driven antibiotic drug discovery by capitalising on recently gained insights into a key bottleneck in anti-bacterial research, namely how compound penetration properties determine efficacy and resistance properties.

Three existing communities forming the TT network are:
1) the partners associated with the multinational program Translocation (www.translocation.eu), part of IMI ND4BB;
2) partner sites from EU-OPENSCREEN, the European Research Infrastructure for chemical biology and screening (www.eu-openscreen.eu);
3) partners from the wider global community working on AMR issues and research.

Translocation (1/2013-6/2018) was one of the largest antibiotic research programs in the world specifically devoted to understanding and to devising ways of increasing antibiotic penetration into bacteria. EUOPENSCREEN began operations in April 2018 and from 2019 onwards will run some 50 chemical biology and academic drug discovery projects per year, across a network of 25 screening sites, based in eight European countries on behalf of users from across Europe. It is anticipated that at least 20% of EU-OPENSCREEN projects will involve antibiotic drug discovery element. The initial goal of the TT network will be to transfer knowledge between Translocation and EU-OPENSCREEN to fully incorporate compound permeation and efflux considerations into academic antibiotic drug discovery. We have the active participation of the Pew Charitable Trust, which will contribute to the long-term systematic dissemination of findings from the co-funded funded Translocation project to help academic antibiotic drug discovery efforts on a global scale.

Network partners

  • Mathias Winterhalter, Jacobs University Bremen, Germany (Coordinator)

This network includes 22 partners, please click on the following link to see complete network composition: Network composition TRANSLOCATION-transfer (TT)

Translocation-transfer aims to improve academically driven antibiotic drug discovery on a key bottleneck in anti-bacterial research, namely how compound penetration determine efficacy and resistance properties. There is an urgent need for discovery and development of new drugs to combat multi-resistant organisms. The search for new drugs is cumbersome, particularly because the current business model for antibiotics in the pharmaceutical industry has stalled because of the poor return on investment. In response to the pharmaceutical industry stepping back from antibiotic discovery, multiple public efforts, including the JPIAMR and IMI ND4BB, as well as the efforts of Biomedical Science (BMS) European Research Infrastructures community have stepped in to fill the gap. Translocation-transfer (TT) brings together experts from with two major publically funded programs, with the goal to improve the process of academically driven antibiotic drug discovery by capitalising on recently gained insights into a key bottleneck in anti-bacterial research, namely how compound penetration properties determine efficacy and resistance properties.

Three main communities form the TT network: i) the partners associated with the multinational program Translocation (www.translocation.eu), part of IMI ND4BB;ii) partner sites from EU-OPENSCREEN, the European Research Infrastructure for chemical biology and screening (www.eu-openscreen.eu) and iii) partners from the wider global community working on AMR issues and research.

Project resources

Publications

Call

Network of European and African Researchers on Antimicrobial Resistance (NEAR-AMR)

The Network of European and African Researchers on Antimicrobial Resistance (NEAR-AMR) represents a group of experts from leading institutions throughout Europe and Africa, within multiple disciplines (clinical, pharmacy, veterinary, environmental microbiology, epidemiology, molecular biology and evolution) encompassing a One Health approach to AMR.

Completed project

The comprehensive geographical spread allows different, country-specific insights into the two focal areas of this network:
1. Determining which common capacity and capability training needs exist for young investigators hoping to establish themselves within any area of AMR research from Europe and Africa.
2. Informing on the preferred profile, and realistic limitations, of global surveillance data sharing platforms, informing expectations on what is possible within a range of existing healthcare infrastructures from multiple geographical settings.

Network outputs will be included within a dedicated NEAR-AMR website, and will inform on the strategic direction of the JPIAMR-VRI as it develops. The overall aim of this network is to focus international efforts for maximal benefit and to ensure that results are translatable on continental scales.

Network partners

  • Adam Roberts, Liverpool School of tropical Medicine, United Kingdom (Coordinator)

This network includes 24 partners, please click on the following link to see complete network composition: Network composition Network of European and African Researchers on Antimicrobial Resistance (NEAR-AMR)

A unique aspect of NEAR-AMR is the geographical spread of its members who are from countries representing a range of different socio-economic and resource settings from two continents: Africa and Europe. The personal experiences and insights from NEAR-AMR members who are from all stages of their careers and who are from a diverse range of fields spanning the entire One Health spectrum (including Pharmacists and clinicians, academics, veterinarians and environmental scientists), has allowed us to formulate a unique perspective on two important topics relevant to the formation of the JPIAMR Virtual Research Institute (VRI).

Firstly we have analysed the globally available reporting platforms for antimicrobial resistance (AMR) surveillance data. We have found the existing platform Global Antimicrobial Resistance Surveillance System (GLASS) supported by the World Health Organisation (WHO) is working well at national scales and is also aspirational for countries with developing healthcare infrastructure. We have also explored the benefits of reporting AMR surveillance data at more local scales and found that there are in fact two sources of information that currently exist which are not utilised as well as they could be. These are prescription data and sales data in the clinical and veterinary / agricultural fields respectively. We have an opportunity to utilise this data, which exists in almost all resource settings, in order to spot local outbreaks of resistance which could result in a change of prescription practices hospital, regional and national scales and in real time.
Secondly; we have investigated the most important training needs for early career researchers and, following discussions and a survey amongst NEAR-AMR members, concluded that strengthening knowledge in the field of diagnostics for infection, closely followed by increasing fundamental knowledge of antibiotics and the use of microbiological results in the clinic would be the top three training priorities. These recommendations will be made to the JPIAMR to inform the development of the VRI.

Project resources

Publications

Call

International Research Alliance for Antibiotic Discovery and Development (IRAADD)

The IRAADD network includes internationally renowned groups with excellent records of accomplishment in AMR research focussing on early stages of antibiotic discovery and development.

Ongoing project

This expert team will include natural products researchers, medical microbiologists, bioinformaticians, medicinal chemists and target-based drug designers, as well advisory partners from global alliances focussing on antibiotic development such as DNDi/GARDP and IMI-ENABLE. The partners of the network will set up a cooperative platform that will allow the sharing of scientific research data, translational knowledge and expert advice for the strategic development of new and advanced projects with the aim to take collaborative scientific research in the early stages of antibiotics discovery and development to a new level. IRAADD believes that such an integrative research network with international outreach will be an important step forward to close the gap in translational drug development, which has been lasting for several decades. IRAADD will represent a consortium of leaders from academia and other sectors who will actively address the worldwide concern of spreading AMR.

While this crisis is steadily expanding, research and development of novel antibiotics is inhibited because of underfinanced discovery and development projects prior to the preclinical trial phase, which are essential to provide new and innovative antibiotics for saving patient lives today and in future. In addition, there is currently no network available to leverage the ideas and projects of academic groups, which typically do not move forward towards application. Thus, our initiative aligns with the current “One Health Action Plan against Antimicrobial Resistance” introduced by the European Commission, which explicitly demands the implementation and support of “research into the development of new antimicrobials” and the establishment of sustainable research networks in this area. However, IRAADD strongly believes that the current situation and available institutions do not efficiently allow for a coordination and coaching especially of academic partners regarding translation of urgently required research on novel antibiotics into clinical use.

Network partners

  • Rolf Müller, Helmholtz Centre for Infection Research, Germany (Coordinator)

This network includes 37 partners, please click on the following link to see complete network composition: Network composition International Research Alliance for Antibiotic Discovery and Development (IRAADD)

Call

inCreasing cOmmunicatioN, awareNEss and data sharing in a global approaCh against resisTance (CONNECT)

The CONNECT network is based on the need for defining and implementing an integrated research strategy to facilitate the necessary studies and investigations for an innovative response to AMR. The CONNECT network output will contribute to the development of the JPIAMR-VRI by aligning stakeholders to share values on AMR with a One Health approach.

Completed project

The CONNECT network will provide an opportunity for stakeholders to consolidate around a common sets of goals, share their lesson learned and identify synergic work and effectively contribute to the collective impact of research. Recognising the complexity and scale of AMR is emphasised by the amount of resources needed to address the issue, and the limits of available resources and organisational capacities of governments, civil society, and philanthropy/charities.

Through partnerships, resources across sectors have the potential to complement one another and create more effective and sustained change. To have increased meaningful and sustainable impact, community engagement is needed. To develop trust, institutions and communities in the network should be involved in design and implementation of research. Developing member interoperability is expected to contribute to a strong and coherent globally connected effort based on exchange data, information, services and/or outputs, align their activities, policies and procedures and effectively operate together.

As an ultimate goal, the platform will encourage the development of priorities on strategic focuses, the engagement of brains thinking out of the box innovative solutions, and will represent the virtual and unique point for governing the research in Europe on the fight against AMR on a One Health approach.

Network partners

  • Nicola Petrosillo, National Institute for Infectious Diseases “Lazzaro Spallanzani”, IRCCS, Italy (Coordinator)

This network includes 20 partners, please click on the following link to see complete network composition: Network composition inCreasing cOmmunicatioN, awareNEss and data sharing in a global approaCh against resisTance (CONNECT)

Antimicrobial resistance (AMR) is one of the biggest public health challenges of our time. AMR is the ability of a microorganism to survive and grow in the presence of antimicrobial drugs, this phenomenon implies that antimicrobials are no longer effective to treat infectious diseases. The AMR problem is very complex and caused by multiple factors; an important cause is represented by the excessive use of antibiotics, not only in humans but also in food animal production and in agriculture. Addressing the growing threat of AMR requires a holistic and multidisciplinary approach – referred to as One Health – which includes all sectors such as hospitals, communities, farm animals, human and animal waste, wastewater systems.

To fight AMR, collaboration between researchers coming from different countries as well as from different scientific fields is essential. For this purpose, the JPIAMR established a virtual research institute (JPIAMR-VRI) with the main scope to improve visibility of the AMR research and facilitate knowledge exchange and capacity development across the globe, covering the full One Health spectrum. The CONNECT (inCreasing cOmmunicatioN, awareNEss and data sharing in a global approaCh against resistance) is one of the eight pillars that lay the foundation of the JPIAMR-VRI. In order to improve knowledge on AMR research and to allow findings sharing, and avoid duplication of research, the CONNECT network prepared a list of main projects and networks related to research on AMR in a One Health Approach. Moreover, links with other networks involved in the AMR research on a One Health approach were established, this will be the basis for a deeper cooperation between researchers across Europe and beyond and, importantly, for an exchange of findings and a sharing of research objectives with scientists working on animal health and on agricultural research.

Our network also prepared a proposal for a communication, dissemination and exploitation (CDE) plan to be used by all the VRI networks. The scope of this plan is to improve communication and dissemination of ideas on research projects and on the findings of projects. This is a tool that will allow to join efforts, minimize duplication and maximize potential of AMR research on a One Health approach. Moreover, the CDE plan will ensure that both the scientific community and the broad public understand the value of the JPIAMR –VRI and the importance of the One Health approach. In fact, to have meaningful and sustainable impact, community engagement is needed. The CONNECT network, along with the VRI networks, laid the foundation stone for developing scientists interoperability.

Publications

Call

Antimicrobial Resistance in Intensive Care (AMRIC)

The AMRIC (Antimicrobial Resistance in Intensive Care) network will use the InFACT infrastructure and collaboration network to spearhead a global acute care initiative for research on antimicrobial resistance.

Ongoing project

InFACT was established by independent investigator-led clinical research groups and academic research consortia to provide a mechanism to build international collaboration, address common needs, and to raise the profile of investigator-driven acute care research with researchers, policymakers, funders and the public. InFACT currently consists of 35 member networks representing every continent and income grouping on the planet and sharing the common goal to advance science and build research capacity. InFACT member networks are the leading research networks in critical care, with embedded mentoring and knowledge exchange activities. AMRIC, using the InFACT model and its pre-existing collaborations, will scale-up a plan for data sharing on the sources, burden, modifiable risk factors, and impact of antimicrobial resistance in acute care settings around the world. Through a recently funded and established mapping platform (ACCESS-MAPS, co-investigator Wallace) and a large team of motivated investigators, AMRIC will implement a plan for clinical and microbiologic data sharing for determining the scale of the AMR problem in acute care settings globally. The AMRIC network has recently conducted scoping reviews on the subject through prior JPIAMR support; this proposal will allow further planning for the implementation of the findings and coordinating the scaling-up of prospective data collection.

Network partners

  • Srinivas Murthy, University of British Columbia, Canada (Coordinator)

This network includes 22 partners, please click on the following link to see complete network composition: Network composition Antimicrobial Resistance in Intensive Care (AMRIC)

Call

AMR Dx Global

AMR Dx Global is a transnational, multi-sectorial, multi-stakeholder and interdisciplinary network focussed on rapid diagnostics training and capacity building to tackle the global threat of antimicrobial resistance with a One Health approach. The network is coordinated by the University of Edinburg and brings together partners from 18 countries including international organisations like WHO, FIND, AMREF and ICAN.

Completed project

AMR Dx Global will develop a Strategic Action Plan on training to support the formation of the JPIAMR-VRI and focus on Diagnostics as one of the six priority topics of the JPIAMR Strategic Research Agenda. AMR Dx Global evolved from the successful JPIAMR Working Group AMR-RDT, which identified barriers to development, implementation and use of rapid diagnostics to tackle AMR. The findings of AMR-RDT has been published in Nature Reviews Microbiology and Lancet Infectious Diseases for publication. As before, AMR Dx Global has assembled an outstanding group of experts selected to match the scope of the JPIAMR VRI.

The new network provides exceptional access to and input from the leading national and international institutions, networks and activities in the field, which amplifies its immediate reach. Most importantly, the extensive coverage of existing global, international and national initiatives relevant to AMR, diagnostics, training, teaching and capacity building constitutes an exceptional opportunity for JPIAMR-VRI to receive input to its strategy and mitigate the risk of duplication amongst the many emerging transnational initiatives on AMR.

AMR Dx Global will run a twelve-month programme including two major meetings and structured data collection on existing strategies, needs and gaps in AMR diagnostics training and capacity building to develop the Strategic Action Plan on training for Diagnostics. The framework for AMR Dx Global and its ultimate vision is the set-up of a JPIAMR Virtual School of Diagnostics as part of the JPIAMR-VRI. Such Virtual School would create world-leading opportunity to connect the global AMR diagnostics community and stakeholders with the next generation of AMR scientists and turn the challenge of AMR into an opportunity for the next generation of researchers and the sustainable development goals.

Network partners

  • Till Bachmann, University of Edinburgh, United Kingdom (Coordinator)

This network includes 42 partners, please click on the following link to see complete network composition: Network composition AMR Dx Global

Diagnostics is one of the most important tools to tackle the global threat of antimicrobial resistance (AMR). AMR Dx Global is an international network with partners in 15 countries funded by the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) as part of the emerging Virtual Research Institute (VRI) and coordinated by University of Edinburgh.

The network addresses the needs for teaching and training in relation to AMR diagnostics from a One Health perspective. The network conducted stakeholder mapping, content and delivery roadmapping as well as a demand survey for teaching and training on AMR diagnostics which includes for any type of diagnostics or test to provide information in the wider context of antibiotics, antibacterial resistance or infection such as tests for bacteria, antibiotic resistance genes, antibiotic susceptibilities, infection biomarkers, or antibiotic residues. The AMR Dx provides input into the formation of the JPIAMR VRI and recommends a strong presence of AMR diagnostics in the emerging platform.

Call

Global Antimicrobial resistance Platform for ONE Burden Estimates (GAP-ONE)

Many global and international institutions and organisations acknowledge the cost of antimicrobial resistance (AMR). Even so, current figures fail to capture the full health and economic burden caused by AMR.

Completed project

Most current estimates are based only on the human health perspective from high-income countries, and a fully One Health integrated approach to the cost estimate is lacking. The entire shadow costs attributable to AMR should consider the worldwide One Health areas. If available, these estimates would constitute a powerful benchmark for advocating in favour of global action against AMR, providing opportunities for evaluating the cost-effectiveness of interventions aiming at tackling AMR and for identifying opportunities for re-allocating resources to research and development of new antimicrobial therapies.

The GAP-ONE network aims to create a virtual research environment that will:
1) Involve all stakeholders into a network that will provide an opportunity for participants from different disciplines to interconnect more fully and effectively.
2) Identify all the data elements required to build a reliable tool for estimating resource waste due to AMR worldwide, in not only human health but also integrating veterinary and environmental data, within a One Health approach.
3)Provide a framework to assess data quality.
4) Devise a strategy for sharing the currently available information.

The GAP-ONE network includes human and veterinary clinicians, human and veterinary microbiologists, experts in antimicrobial resistance burden, food safety, health-economics, and international law, as well as infection control experts, clinical epidemiologists, statisticians, and health information librarians. As part of this proposal, the network will involve additional stakeholders, such as patient organisations, drug and diagnostics manufacturers, and experts in social sciences, behavioural change experts, health authorities, and governmental agencies. The network aims to include all stakeholders in the “AMR stakeholder mapping” done by ReAct Europe – Action on Antibiotic Resistance a global mapping of stakeholders working with antimicrobial resistance.

Network partners

  • Luigia Scudeller, IRCCS Policlinic San Matteo Foundation, Italy (Coordinator)

This network includes 20 partners, please click on the following link to see complete network composition: Network composition Global Antimicrobial resistance Platform for ONE Burden Estimates (GAP-ONE)

How much does antimicrobial resistance cost? The overall worldwide cost attributable to it is certainly high, but remains largely unknown. The economic studies performed so far only consider direct costs associated with human infection from a hospital perspective, primarily from high-income countries. But antimicrobial resistance is a One Health issue: it applies to human, animal, and environmental health.

We have developed a framework, called The Global Antimicrobial Resistance Platform for ONE-Burden Estimates (GAP-ON€), that shows the immense number of often hidden, human, animal and environmental costs across the many individual and societal dimensions, inextricably linked together in a One Health picture. There are many bacteria (but other germs as well) that can colonize or even cause disease in human beings and animals, in a common environment. These cause direct health costs (costs of medicines, hospital stay, diagnostic tests, etc) and also indirect costs (loss of working days, loss of farm animals in the food chain, insurance costs etc). Building on this framework, future studies will be able to assess more precisely what the costs of antimicrobial resistance are, and will hopefully increase global public awareness of the real burden of AMR in all areas of life, across the world.

Publications

Call

JPIAMR-VRI Network Call 2018

JPIAMR recognises a need to reinforce alignment of research. To promote this, the JPIAMR will establish a Virtual Research Institute in AMR (“the JPIAMR-VRI”) – a Global Network connecting research performing organisations, institutes, centres, and infrastructures. This Network call aims to identify research community needs and develop ideas to form the foundation for the JPIAMR-VRI.

The intent of the call is to form Networks of motivated groups to conceptualise and develop the JPIAMR-VRI. The Networks should identify research community needs, develop catalytic ideas and strategic plans to help bring the JPIAMR-VRI to Life!

Up to 21 Networks will be funded with up to 50,000 € each to connect experts from research performing organisations, institutes, centres and infrastructures and establish expertise clusters in the AMR community. Note that JPIAMR Network calls do not fund research projects.

Scope of the call

The JPIAMR-VRI will provide a platform to increase coordination, improve visibility of the AMR researcher base, facilitate knowledge exchange and capacity development across the globe, covering the full One Health spectrum.The JPIAMR-VRI is expected to:

  1. Connect AMR researchers across the JPIAMR priority topics in a One Health approach
  2. Build capacity and strengthen capability in AMR research
  3. Facilitate access to scientific information and infrastructures
  4. Bridge geographic borders in the research community through global reach
  5. Break practical barriers between geographies and fields of research
  6. Increase awareness and visibility of the issue of AMR and the importance of research in tackling this
  7. Encourage the use of scientific evidence to inform policy and guideline makers

Expected Outcome

Applicants are invited to form JPIAMR Networks that are expected to provide plans to develop the JPIAMR-VRI.

Suggested focal areas

JPIAMR Networks may tackle one or more of the suggested focal areas below. These examples are neither mandatory nor limiting. Network tasks should address needs at a National and International level, include Low and Middle Income Country (LMIC) aspects and consider the One Health approach.

Examples of Network focal areas could include, but are not limited to:

  • Develop blueprints on: strategic focus, governance, funding/sustainability, infrastructure, engagement, implementation, the unique selling point of the JPIAMR-VRI, and/or addressing innovative “out of the box” ideas.
  • Develop a Communication and Knowledge Translation Strategy.
  • Develop a Partnerships Strategy to ensure key stakeholders, including industry and policy makers, and other networks are engaged and coordinate the alignment of other funded Networks.
  • Develop a Strategic Action Plan on Training to identify opportunities for capacity building and strengthen capability, with a focus on young investigators.
  • Develop a plan for a Global Platform for data sharing (e.g. clinical samples/data, scientific information and infrastructures including libraries or catalogues)
  • Develop a Map of other funded Networks (e.g. current information on expertise, fields of interest, demographics, available technologies and resources)

Information & application

This call is closed.

A startup workshop for all funded networks from the two transnational network calls launched by JPIAMR in 2018, JPIAMR Network Call on Surveillance and JPIAMR-VRI Network Call 2018, was organised in Amsterdam, The Netherlands in February 2019. The workshop report can be found here: Startup workshop report 2018 JPIAMR Transnational Networks.

Filmed interviews with the coordinators of the funded JPIAMR Networks can be found here: Discover the JPIAMR-VRI: Interviews with network coordinators February 2019

Funders

Canada
Canadian Institute of Health Research (CIHR)

Egypt
Academy of Scientific Research & Technology (ASRT)

France
French National Research Agency (ANR)

Germany
The Federal Ministry of Education and Research (BMBF)

Italy
Ministry of Health (It-MOH)

The Netherlands
The Netherlands Organisation for Health Research and Development (ZonMw)

Norway
The Research Council of Norway (RCN)

Spain
Instituto de Salud Carlos III

Sweden
Swedish Research Council (SRC)

United Kingdom
Medical Research Council (MRC)

Supported projects

Eight networks were funded within the JPIAMR 2018 call for transnational networks “Building the Foundation of the JPIAMR Virtual Research Institute.” Each funded network received €50,000 to establish expertise clusters to identify research community needs and develop ideas to form the foundation for the JPIAMR Virtual Research Institute (JPIAMR-VRI). Click on the network titles in the list below to learn more on each network.